Neurocrine Biosciences.
American biopharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 68
What's happening
Earlier this month
One to three months ago
-
Neurocrine Biosciences and Rhythm are both targeting the rare obesity market.Some support1 report
-
HHS and the White House are involved in policy discussions regarding generic drugs, including potential agreements concerning U.S. tariffs and the tardive dyskinesia market.Some support1 report
-
Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.Some support2 reports
-
Neurocrine Biosciences filed reports with the SEC on August 16, 2026.Some support2 reports
Gone quiet
No new reports in 90+ days-
Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.Some support2 reports
-
Access to the drug INGREZZA is now contingent on coverage through the Medicare system.Some support3 reports1 development inside
-
Citigroup issued a buy rating and price target for Neurocrine Biosciences, with MarketBeat reporting stock average rating.Some support1 report
-
Neurocrine Biosciences, a company, is based in San Diego, CA.Well supported3 reports
-
Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment.Some support2 reports1 development inside
-
Neurocrine Biosciences is developing INGREZZA for Huntington's disease, utilizing Kinect data in the KINECT-HD study.Speculative1 report
-
Neurocrine presented data on the CAHtalyst Adult study, which utilized Crenessity for managing classic Congenital Adrenal Hyperplasia (CAH), at the Endocrine Society's Annual Meeting.Some support3 reports
-
Morgan Stanley raised its price target for Neurocrine Biosciences stock, a company that develops treatments for Huntington's chorea.Some support7 reports
-
Neurocrine's Valbenazine study failed its primary endpoint for schizophrenia, while CRENESSITY and INGREZZA reported mixed sales results.Some support2 reports
-
Neurocrine Biosciences stock outperformed the S&P 500 composite on July 31, 2025.Some support1 report
-
Neurocrine Biosciences and AbbVie collaborated on treatments for chorea associated with Huntington's disease.Some support2 reports
-
Neurocrine Biosciences and Grifols are both medical drugs stocks.Some support1 report
-
Neurocrine Biosciences presented at a TD Cowen summit in August 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Neurocrine Biosciences this week
News at the entities that move Neurocrine Biosciences most-
FDA StructuralDBV Technologies is seeking regulatory acceptance for its product from the FDA.Moves Neurocrine Biosciences
-
Citigroup Mentioned togetherCitigroup issued a neutral rating on Genpact shares, while TD Cowen reduced its price target and set a buy rating.Moves Neurocrine Biosciences
-
Medicare StructuralSEC legally requires fiduciaries to prioritize client interests, and Roth withdrawals avoid Medicare and Social Security taxation.Moves Neurocrine Biosciences
-
Needham & Company OperationalNeedham & Company provided research reports on Geron Corporation, coinciding with a filing with the SEC confirming institutional investment activity.Moves Neurocrine Biosciences
-
Morgan Stanley Mentioned togetherAnalyst rating updates for IONQ as of June 19, 2026, with Jefferies setting a $85 price target and Morgan Stanley lowering theirs to $48.50.Moves Neurocrine Biosciences
-
MarketBeat Mentioned togetherFreedom Capital lowered its rating for Genie Energy, while MarketBeat provided average rating data.Moves Neurocrine Biosciences
Connections
The 20 strongest of 68, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Neurocrine Biosciences is required to file various reports and disclosures with the SEC.
-
FDA Structural
Neurocrine Biosciences' market viability and growth are structurally dependent on regulatory approval from the FDA.
-
Medicare Structural
Neurocrine Biosciences' market access for its products relies on coverage and payment through the Medicare program.
-
AbbVie Operational
AbbVie and Neurocrine engage in strategic collaborations and partnerships regarding specific treatments.
-
Needham & Company Operational
Needham & Company provides financial analysis and adjusts price objectives for Neurocrine Biosciences based on its performance.
-
Citigroup Mentioned together
Citigroup provides financial ratings and price targets for Neurocrine Biosciences.
-
Nxera Pharma Operational
The companies are engaged in a collaborative partnership to advance the development of the asset NBI-1117567, which originated from a rights acquisition by Nxera from Neurocrine.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis, including price targets and ratings, for Neurocrine Biosciences.
Show all 20 connections
-
MarketBeat Mentioned together
MarketBeat provides financial data, stock ratings, and analyst recommendations for Neurocrine Biosciences.
-
Rhythm Operational
Both companies are actively competing in the specialized rare obesity market.
-
TD Cowen Mentioned together
TD Cowen provides financial research, price targets, and ratings for Neurocrine Biosciences.
-
Truist Financial Transactional
Truist Financial has issued price targets and buy ratings on Neurocrine Biosciences stock.
-
Benzinga Mentioned together
Benzinga, a financial news service, reports on Neurocrine Biosciences' market developments, including price targets and clinical updates.
-
Leerink partners Mentioned together
Leerink Partners has provided analyst coverage, including raising the target price, for Neurocrine Biosciences.
-
Nasdaq Shared context
Neurocrine Biosciences is a company listed and traded on the Nasdaq stock exchange.
-
Perrigo Company Plc Mentioned together
The entities are co-mentioned in the context of being compared as healthcare companies.
-
San Diego Shared context
Neurocrine Biosciences is based in San Diego, CA, and conducts its operations within the city.
-
George Morrow Transactional
George Morrow, a director, sold company stock under a trading plan.
-
Crinetics Pharmaceuticals Mentioned together
Co-mention observed in articles discussing the pharmaceutical sector, though the specific evidence relates to Neurocrine's unrelated acquisition of Soleno Therapeutics.
-
Kinect Mentioned together
The evidence describes Kinect's use in studies but does not explicitly link it to Neurocrine Biosciences.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
3 events- Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.
- Neurocrine Biosciences filed reports with the SEC on August 16, 2026.
- Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.
Show 2 earlier months
July 2026
2 eventsJune 2026
11 events- Xenon and Neurocrine Biosciences announced a partnership on August 12, 2025, allowing collaboration and milestone payments regarding Azetukalner, which is Xenon's lead pipeline candidate.
- Neurocrine Biosciences, a company, is based in San Diego, CA.
- Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment.
- Neurocrine Biosciences is developing INGREZZA for Huntington's disease, utilizing Kinect data in the KINECT-HD study.
- Neurocrine presented data on the CAHtalyst Adult study, which utilized Crenessity for managing classic Congenital Adrenal Hyperplasia (CAH), at the Endocrine Society's Annual Meeting.
- Morgan Stanley raised its price target for Neurocrine Biosciences stock, a company that develops treatments for Huntington's chorea.
- Neurocrine's Valbenazine study failed its primary endpoint for schizophrenia, while CRENESSITY and INGREZZA reported mixed sales results.
- Neurocrine Biosciences stock outperformed the S&P 500 composite on July 31, 2025.
- Neurocrine Biosciences and AbbVie collaborated on treatments for chorea associated with Huntington's disease.
- Neurocrine Biosciences and Grifols are both medical drugs stocks.
- Neurocrine Biosciences presented at a TD Cowen summit in August 2025.